Anti Osteoporosis Therapy and Fracture Healing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Calcitonin is the fastest growing sector, North America is the largest market

The global market for anti-osteoporosis therapy and fracture healing is projected to expand significantly, rising from USD 15.34 billion in 2025 to USD 19.97 billion by 2031, at a compound annual growth rate of 4.49%. This market encompasses pharmaceutical formulations and medical devices specifically designed to maintain bone density and accelerate the healing of skeletal fractures. Its expansion is largely fueled by the world's aging population and the resulting increase in osteopenia and fragility fractures. Furthermore, the growing financial burden of bone disorders mandates effective therapeutic interventions to alleviate long-term healthcare costs; for example, the Bone Health and Osteoporosis Foundation estimated that the national costs of osteoporotic fractures would exceed $95 billion by 2030.

Nevertheless, a key impediment to market growth is the high rate of patient nonadherence to antiresorptive therapies, often driven by worries about rare adverse events. This apprehension among patients and healthcare providers concerning starting or continuing treatment creates a substantial treatment gap, thereby limiting the effective reach of available therapies. Consequently, overcoming these barriers to treatment uptake remains a critical challenge for industry stakeholders aiming to maximize market penetration and enhance global patient outcomes.

Market Drivers

The primary driver for the market is the rapidly aging global population and increased life expectancy, which significantly expands the patient demographic vulnerable to skeletal fragility. These demographic shifts lead to a higher incidence of low bone mass and related injuries, demanding immediate therapeutic interventions and management. This demographic pressure creates a substantial clinical burden, boosting demand for diagnostic screenings and preventive care; for instance, the International Osteoporosis Foundation reported in August 2024 that up to 37 million fragility fractures occur globally each year, highlighting the immense scale of the problem. The profound economic and social repercussions of these injuries further pressure healthcare systems to address the treatment gap, as evidenced by the Royal Osteoporosis Society's March 2024 statement indicating that the absence of effective fracture liaison services causes 4,200 preventable hip fractures annually in the UK alone.

A second crucial catalyst is the progress in novel anabolic and antiresorptive drug therapies, offering clinicians more powerful choices for managing high-risk patients. Pharmaceutical firms are heavily investing in biologics that not only prevent bone resorption but also encourage new bone formation, providing superior effectiveness for individuals with severe osteoporosis. This innovation translates into significant revenue growth and affirms the commercial potential of advanced treatments; for example, Amgen's October 2024 financial results showed a 6% year-over-year increase in Prolia sales, reaching $1.0 billion for the quarter. The sustained commercial success of such branded therapies underscores a strong market preference for agents that offer proven safety profiles and measurable improvements in bone mineral density.

Market Challenges

The foremost challenge impeding the expansion of the Global Anti Osteoporosis Therapy and Fracture Healing Market is the persistent issue of patient nonadherence, largely fueled by concerns over rare adverse events. Despite antiresorptive therapies being clinically proven to diminish fracture risks, apprehension regarding potential side effects, such as osteonecrosis of the jaw or atypical femoral fractures, creates significant reluctance among both patients and healthcare providers. This psychological barrier not only hinders the initiation of essential drug regimens but also results in high discontinuation rates, thus disrupting revenue streams for pharmaceutical manufacturers and restricting the adoption of advanced therapeutic devices.

This reluctance directly limits market volume by creating a vast disparity between the eligible patient population and those actually receiving treatment. The resulting treatment gap ensures that a large portion of the market remains underserved, stifling potential revenue growth despite the increasing prevalence of bone disorders. The scale of this unaddressed opportunity is substantial; according to the International Osteoporosis Foundation, in 2025, up to 80% of patients globally who experience a fragility fracture remain undiagnosed and untreated for the underlying condition. This statistic underscores a critical failure to translate high disease prevalence into sustained market engagement, thereby fundamentally undermining the industry’s growth trajectory.

Market Trends

The market is undergoing a significant structural shift due to the introduction of biosimilars for major osteoporosis biologics, especially as patents for blockbuster RANK ligand inhibitors expire. This trend is breaking down exclusivity barriers, intensifying price competition, and considerably improving patient access to highly effective treatments that were previously too expensive for long-term management.

The availability of these more affordable alternatives prompts healthcare systems to expand reimbursement criteria, consequently increasing the number of treated patients; for instance, Managed Healthcare Executive reported in February 2025 that the FDA approved Samsung Bioepis' biosimilars Ospomyv and Xbryk for osteoporosis and bone metastases, signaling heightened market rivalry. This series of regulatory approvals not only lowers healthcare costs but also compels originator companies to innovate new mechanisms to retain their market share.

Simultaneously, a strong focus on innovation in non-invasive drug delivery systems is addressing the ongoing challenge of patient reluctance towards injectable anabolic therapies. Industry participants are developing oral formulations of parathyroid hormone analogs, which are expected to offer efficacy similar to subcutaneous injections while substantially boosting adherence rates among older demographics.

This development tackles both the logistical and psychological hurdles associated with daily self-injections, which have historically resulted in high discontinuation rates; for example, Entera Bio's September 2025 press release highlighted Phase 2 data from the ASBMR Annual Meeting, showing that the oral PTH(1-34) tablet EB613 achieved significant cortical bone parameter increases comparable to established injectable agents after six months. The successful commercialization of these oral options represents a crucial change in treatment approaches, providing a convenient, patient-centric choice for managing severe osteoporosis.

Key Market Players

• GlaxoSmithKline plc
• Medtronic Plc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer inc.
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.
• Orthofix US LLC

Report Scope

In this report, the Global Anti Osteoporosis Therapy and Fracture Healing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti Osteoporosis Therapy and Fracture Healing Market, by Drug Type:

• Calcitonin
• Bisphosphonates
• Hormone Replacement Therapy
• Anabolic
• Others

Anti Osteoporosis Therapy and Fracture Healing Market, by Route of Administration:

• Oral
• Injectable

Anti Osteoporosis Therapy and Fracture Healing Market, by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

Anti Osteoporosis Therapy and Fracture Healing Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti Osteoporosis Therapy and Fracture Healing Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.